DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (AATD)

Information source: University of Florida
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Liver Fibrosis; Alpha-1 Antitrypsin Deficiency; AAT Deficiency; AATD

Intervention: Abdominal ultrasound (Device); History and physical (Procedure); Intravenous catheter (Procedure); Blood draw (Procedure); Liver questionnaire (Other); Liver Biopsy (Procedure); Midazolam (Drug); Fentanyl (Drug); Lidocaine (Drug); Acetaminophen (Drug); Lorazepam (Drug); Oxycodone/Acetaminophen (Drug); Ondansetron (Drug)

Phase: Phase 1

Status: Recruiting

Sponsored by: University of Florida

Official(s) and/or principal investigator(s):
Mark Brantly, MD, Principal Investigator, Affiliation: University of Florida

Overall contact:
Tracie L Kurtz, RN, CCRP, Phone: 866-229-6313, Email: tlkurtz@ufl.edu


We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.

Clinical Details

Official title: Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: To estimate the prevalence and histologic spectrum of liver injury in an adult with Alpha-1 Antitrypsin deficiency having a ZZ genotype or other rare allele.

Secondary outcome:

To identify environmental and host risk factors for clinically significant liver fibrosis.

To define the diagnostic accuracy of non-invasive markers of fibrosis in AAT liver disease.

To explore epigenetic markers for the development of liver fibrosis.

To quantify liver fibrosis progression.

Detailed description: Our overarching hypothesis is that liver disease in adults with AAT deficiency is the result of the accumulation of the abnormally folded protein within the endoplasmic reticulum of the hepatocyte. In some individuals, the intrinsic cellular mechanisms of the hepatocyte are sufficient to clear adequate amounts of the abnormally folded protein such that liver disease does not occur. In AAT deficient individuals who develop liver disease, environmental and other genetic factors stress the hepatocyte, and the normal cellular mechanisms that maintain homeostasis are disrupted, leading to liver disease. For this proposal, our hypothesis is that the prevalence of liver disease in adults with AAT is higher than previously reported because liver injury and fibrosis is not accurately detected by available routine liver testing. Testing this hypothesis will require an initial evaluation for liver disease with liver function testing and imaging, and then histologic confirmation by liver biopsy.


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria:

- Alpha-1 Antitrypsin deficiency confirmed to be PI*ZZ by both genotype or another

identified rare allele;

- Age range from 18-70;

- Willingness to consent to liver biopsy;

- Ability to travel to UF as necessary by protocol; and

- Platelet count greater than or equal to 50,000/mm3 and an INR less than or equal to

1. 5. Exclusion Criteria:

- Hemophilia, anticoagulant therapy that cannot be interrupted briefly, malignancy, or

any other condition that would compromise the safety of a liver biopsy;

- Any known pre-existing medical condition that might interfere with the patient's

participation in and completion of the study or any condition, which in the opinion of the investigator would make the patient unsuitable for enrollment;

- Active substance abuse including, but not limited to, alcohol, intravenous or,

inhaled drugs;

- History of adverse reactions or allergy to the local anesthetic, sedative, or

pre-medication used for the percutaneous liver biopsy;

- Poor venous access making the subject unable to complete the required laboratory

testing schedule; and

- Females who are pregnant or lactating at time of enrollment. Should a female subject

become pregnant during the follow up period after the initial liver biopsy, continued participation would be allowed if the following conditions are met: the subject desires to continue; a discussion of risk and benefits of participation between the principal investigator and the subject has occurred; and no liver biopsy would be performed in the follow up period.

Locations and Contacts

Tracie L Kurtz, RN, CCRP, Phone: 866-229-6313, Email: tlkurtz@ufl.edu

Shands at the University of Florida, Gainesville, Florida 32610, United States; Recruiting
Tracie L Kurtz, RN, Phone: 866-229-6313, Email: tlkurtz@ufl.edu
Virginia C Clark, MD, Phone: 352-273-9491, Email: Virginia.Clark@medicine.ufl.edu
Mark Brantly, MD, Principal Investigator
Virginia C Clark, MD, Sub-Investigator
Additional Information

Starting date: October 2013
Last updated: July 22, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017